The Full Wiki

More info on Ocrelizumab

Ocrelizumab: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Ocrelizumab ?
Monoclonal antibody
Source recombinant
Target CD20
Identifiers
CAS number 637334-45-3
ATC code none
Chemical data
Formula C6494H9978N1718O2014S46 
Mol. mass 148 kDa
Therapeutic considerations
Pregnancy cat.  ?
Legal status

Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets mature B lymphocytes[1] and hence is an immunosuppressive drug candidate. It is under development by Hoffmann–La Roche's subsidiary Genentech, and Biogen Idec.

It had reached Phase III clinical trials for rheumatoid arthritis[2] and lupus erythematosus[3], and Phase II for multiple sclerosis[4] and hematological cancer.[5]

In March 2010, Roche announced the suspension of clinical trials in rheumatoid arthritis and lupus erythematosus. This step followed the occurrence of deaths due to opportunistic infections while development for multiple sclerosis is ongoing.[6]

See also

  • Rituximab, a chimeric CD20 antagonist.
  • Ofatumumab (HuMax-CD20) a fully-human CD20 antagonist.

References

  1. ^ K. John Morrow Jr (2008-06-15). "Methods for Maximizing Antibody Yields". Genetic Engineering & Biotechnology News (Mary Ann Liebert, Inc.): p. 36. http://www.genengnews.com/articles/chitem.aspx?aid=2514. Retrieved 2008-07-06.  (Note: information included in this article only found in table present in print version of article.)
  2. ^ Kausar, F; Mustafa; Sweis; Sawaqed; Alawneh; Salloum; Badaracco; Niewold et al. (2009). "Ocrelizumab: a step forward in the evolution of B-cell therapy". Expert opinion on biological therapy 9 (7): 889–95. doi:10.1517/14712590903018837. PMID 19463076. 
  3. ^ ClinicalTrials.gov
  4. ^ ClinicalTrials.gov
  5. ^ Hutas, G (2008). "Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies". Current opinion in investigational drugs (London, England : 2000) 9 (11): 1206–15. PMID 18951300. 
  6. ^ Katie Reid (2010-03-08). Update 2. Roche suspends arthritis treatment after deaths. Reuters. Retrieved 2010-03-08.
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message